HomeSTIM • NASDAQ
add
Neuronetics Inc
Previous close
$3.83
Day range
$3.78 - $4.04
Year range
$1.03 - $5.07
Market cap
115.40M USD
Avg Volume
185.09K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 20.31M | 11.63% |
Operating expense | 20.10M | -6.67% |
Net income | -5.38M | 35.14% |
Net profit margin | -26.47 | 41.89% |
Earnings per share | -0.19 | 36.67% |
EBITDA | -1.92M | 72.99% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 59.68M | -15.16% |
Total assets | 115.83M | -0.90% |
Total liabilities | 81.64M | 36.47% |
Total equity | 34.19M | — |
Shares outstanding | 29.76M | — |
Price to book | 3.25 | — |
Return on assets | -5.81% | — |
Return on capital | -6.94% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -5.38M | 35.14% |
Cash from operations | 2.13M | 168.81% |
Cash from investing | -563.00K | -11.93% |
Cash from financing | 22.26M | 8,985.71% |
Net change in cash | 23.83M | 809.65% |
Free cash flow | 3.23M | 400.22% |
About
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Neuronetics became "first and only Food and Drug Administration approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device."
They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head. Wikipedia
Founded
2003
Headquarters
Website
Employees
203
